What is the appropriate treatment for allergic conjunctivitis?

Treatment of Allergic Conjunctivitis

Start with topical antihistamine/mast cell stabilizer combination agents as first-line therapy for allergic conjunctivitis, escalating to short-course topical corticosteroids (1-2 weeks) if symptoms remain uncontrolled. 1

Stepwise Treatment Algorithm

First-Line: Conservative Measures + Topical Therapy

• Environmental modifications: Minimize allergen exposure through hand hygiene, hypoallergenic bedding, frequent clothes washing, showering before bedtime, and wearing sunglasses as barriers to airborne allergens 1
• Symptomatic relief: Cool compresses and refrigerated preservative-free artificial tears to dilute allergens and inflammatory mediators on the ocular surface 1
• Topical dual-action agents: Medications combining antihistamine and mast cell stabilizing properties are preferred for both acute and chronic disease 1

The 2024 American Academy of Ophthalmology guidelines emphasize that these combination agents are more effective than older single-mechanism drugs and can be used for either acute exacerbations or chronic maintenance. 1

Second-Line: Short-Course Topical Corticosteroids

• When to escalate: If symptoms are not adequately controlled with first-line therapy 1
• Duration: Brief course of 1-2 weeks using corticosteroids with low side-effect profiles 1
• Monitoring requirement: Baseline and periodic IOP measurement and pupillary dilation to evaluate for glaucoma and cataract if corticosteroids are used chronically or recurrently 1

Third-Line: Immunomodulators for Severe/Refractory Cases

• Topical cyclosporine 0.05%: Use at least four times daily for severe cases; effective in preventing seasonal recurrences 1
• Topical tacrolimus: Consider for patients who have failed therapy with corticosteroids, cyclosporine, and/or antiallergy medications 1
• Cyclosporine 0.1%: FDA-approved specifically for vernal keratoconjunctivitis in children and adults 1

Important Caveats and Pitfalls

Avoid Oral Antihistamines as Primary Therapy

Oral antihistamines may induce or worsen dry eye syndrome and impair the tear film's protective barrier, potentially worsening allergic conjunctivitis. 1 If used, combine with cooled preservative-free artificial tears. 1

Avoid Punctal Plugs

Punctal plugs prevent flushing of allergens and inflammatory mediators from the ocular surface and should be avoided. 1 Associated eye rubbing may increase risk of plug extrusion and canalicular complications. 1

Chronic Vasoconstrictor Use

Chronic use of over-the-counter vasoconstrictor agents can cause rebound vasodilation once stopped. 1

Monitor for Keratoconus Progression

Allergic conjunctivitis and atopic disease are associated with keratoconus—adequate control of allergy and eye rubbing are critical to decrease progression of ectasia. 1 Vernal and atopic keratoconjunctivitis should be controlled prior to corneal cross-linking to decrease risk of sterile keratitis. 1

Immunomodulator Risks

Tacrolimus and cyclosporine may increase susceptibility to herpes simplex keratitis. 1 Tacrolimus and pimecrolimus are rarely associated with skin cancer or lymphoma. 1

Special Populations

Vernal Keratoconjunctivitis (VKC)

• Acute exacerbations: Topical corticosteroids are usually necessary to control severe symptoms (strong recommendation) 1
• Maintenance: Topical cyclosporine 0.1% is FDA-approved for VKC and allows reduced steroid use 1
• Refractory cases: Supratarsal injection of corticosteroid for severe sight-threatening disease not responsive to topical therapy 1

Atopic Conjunctivitis

• Eyelid involvement: In patients ≥2 years old, treat with pimecrolimus cream 1% or topical tacrolimus ointment (0.03% for ages 2-15 years; 0.03% or 0.1% for ≥16 years) 1
• Systemic therapy: Rarely warranted, but options include montelukast, aspirin, and oral T-cell inhibitors (discretionary recommendation with insufficient evidence) 1

Adjunctive Considerations

Allergen-Specific Immunotherapy

Subcutaneous or sublingual immunotherapy is useful for patients with disease inadequately controlled with topical medications, though usage may be limited by expense, long-term commitment, and anaphylaxis risk. 1 Intralymphatic immunotherapy provides short-term benefits but has unclear efficacy beyond one year. 1